St. Jude touts study in support of its fractional flow reserve cardiology tech

At the European Society of Cardiology Congress in London, St. Jude Medical ($STJ) touted the 5-year results of a trial of its fractional flow reserve (FFR) devices. The company said use of its FFR technology results in improved clinical decision making during percutaneous coronary interventions, such as stent implantation. In patients with multivessel coronary artery disease, FFR-guided PCI resulted in a 27 percent relative reduction of cardiac mortality versus angiography alone, the company said. "The five-year data from the FAME study build upon our understanding of applying FFR to guide the care of patients battling coronary artery disease, and this study has continued to demonstrate that St. Jude Medical's PressureWire technology can improve patient outcomes and the clinical benefits of PCI, while reducing costs for the healthcare system," said the company's chief medical officer, Dr. Mark Carlson. More

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.